# Emapalumab Prevention of CAR-T Cell Associated Toxicities

> **NCT06550141** · PHASE2 · RECRUITING · sponsor: **Marcela V. Maus, M.D.,Ph.D.** · enrollment: 28 (estimated)

## Conditions studied

- Large B-cell Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma
- Primary Mediastinal Large B-cell Lymphoma
- High-grade B-cell Lymphoma
- Follicular Lymphoma

## Interventions

- **DRUG:** Emapalumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine Phosphate
- **DRUG:** Axicabtagene Ciloleucel

## Key facts

- **NCT ID:** NCT06550141
- **Lead sponsor:** Marcela V. Maus, M.D.,Ph.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-18
- **Primary completion:** 2026-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06550141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06550141, "Emapalumab Prevention of CAR-T Cell Associated Toxicities". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06550141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*